Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA4 | P51532 | 6/20 | 0.57 |
| ▸ | PBRM1 | Q86U86 | 4/20 | 0.51 |
| ▸ | PER2 | O15055 | 1/20 | 0.44 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.44 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | C1R | P00736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21931873 | 1.00 | SMARCA4 (0.57) | SMARCA4PBRM1PER2CRY1CRY2 | |
| SCHEMBL30139674 | 1.00 | SMARCA4 (0.57) | SMARCA4PBRM1PER2CRY1CRY2 | |
| SCHEMBL30859441 | 1.00 | SMARCA4 (0.57) | SMARCA4PBRM1PER2CRY1CRY2 | |
| SCHEMBL20704878 | 0.86 | SMARCA4 (0.49) | SMARCA4PBRM1MAPTMEN1KMT2A | |
| SCHEMBL20704877 | 0.86 | SMARCA4 (0.49) | SMARCA4PBRM1MAPTMEN1KMT2A | |
| SCHEMBL25053615 | 0.84 | SMARCA4 (0.58) | SMARCA4PBRM1CCR3NPC1RAB9A | |
| SCHEMBL30859440 | 0.83 | SMARCA4 (0.52) | SMARCA4PBRM1MEN1KMT2AL3MBTL1 | |
| SCHEMBL20704901 | 0.83 | SMARCA4 (0.52) | SMARCA4PBRM1MEN1KMT2AL3MBTL1 | |
| SCHEMBL20704903 | 0.83 | SMARCA4 (0.52) | SMARCA4PBRM1CA12CA9MAPT | |
| SCHEMBL21992747 | 0.81 | SMARCA4 (0.58) | SMARCA4PBRM1CCR3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060985-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | GALECTIN SCIENCES, LLC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12377102-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | GALECTIN SCIENCES, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| US-20230116370-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | GALECTIN SCIENCES, LLC | 2023-04-13 | — | — | US | disclosed |
| US-11583530-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | GALECTIN SCIENCES, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| US-20200147088-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | GALECTIN SCIENCES, LLC | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060985-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | LGALS3, LGALS1, LGALS2 | SMARCA4 4289/4885PBRM1 3332/4885PER2 3453/4885 |
| US-20230116370-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | LGALS1, LGALS2, LGALS3 | SMARCA4 4569/4885PBRM1 4399/4885PER2 3913/4885 |
| US-20200147088-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | LGALS1, LGALS2, LGALS3 | SMARCA4 4569/4885PBRM1 4399/4885PER2 3913/4885 |
| US-11583530-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | LGALS1, LGALS2, LGALS3 | SMARCA4 4569/4885PBRM1 4399/4885PER2 3913/4885 |
| US-12377102-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | LGALS1, LGALS2, LGALS3 | SMARCA4 4569/4885PBRM1 4399/4885PER2 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.